Abstract
Objective To explore the expressiom of liver-intestine (CDH17) in gastric cancer and its correlation with prognosis. Methods CDH17 protein expression was detected by immunohistochemistry on tissue microarray, which containing 264 samples of primary gastric cancer and the corresponding paracancerous tissue,and 104 paired lymph node metastases (LNM). Results CDH17 was up-regulated in gastric cancer compared with paired nomal gastric mucosa and correlated with clinical stage,invasion depth,LNM,distant metastasis. Immnoreactivity of CDH17 was significantly higher in LNM than in primary gastric cancer and normal mucosa. There was a negative correlation between the high expression of CDH17 and overall survival (OS) or disease free survival (DFS) of gastric cancer patients. CDH17 was an independent prognostic factor for OS [hazard ratio ( HR) 3. 97 ; 95% confidence interval ( CI) 1. 39-10. 28; P ＜ 0. 05] and DFS (HR 2. 32 ;95% CI 1.17-4. 52; P ＜ 0. 05). Conclusion CDH17 may play an important role in gastric cancer progression and could serve as a biomarker to identify patients at risk of metastasis or recurrence after gastrectomy. Key words: CDH17; Gastric cancer; Diagnosis; Tumor marker
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
